01884nas a2200181   4500000000100000008004100001260001200042653002100054100001500075700001500090700001400105245009800119856010600217300001400323490000700337520133300344022002501677       2023                            d  bMedknow10aGeneral Medicine1 aRamasamy S1 aGalhotra A1 aAgrawal S00aAdverse reactions after Covid-19 vaccination in persons affected by leprosy: A scoping review  uhttps://journals.lww.com/jfmpc/_layouts/15/oaks.journals/downloadpdf.aspx?an=01697686-202312090-00004  a1771-17740 v123 a<p><strong>Background:</strong> Leprosy reactions are the main pathway leading to severe nerve damage and disability. These reactions can occur at any time. The coronavirus disease 2019 (Covid-19) pandemic led to a catastrophic loss of human life and has had a devastating impact on persons affected by leprosy.</p>

<p><strong>Objective: </strong>To achieve deep insight into the subject of adverse reactions acquired after Covid vaccinations in persons affected by leprosy through a literature review.</p>

<p><strong>Materials and Methods:</strong> A scoping review was conducted in the studies published between July 2021 and June 2022 using the Preferred Reporting Items for Systematic Review and Meta-Analysis Extension for Scoping Reviews (PRISMA-ScR) checklist.</p>

<p><strong>Results:</strong> Using the search strategy, a total of 130 articles were found, of which five were relevant to the study. The adverse reactions were acquired mostly in males [9 (81.8%)]; the majority of them belong to borderline tuberculoid [4 (36.4%)], and most of them were released from treatment (multi-drug therapy) [7 (63.6%)].</p>

<p><strong>Conclusion: </strong>Surveillance and management of adverse events following immunization (AEFI) are essential; even minor AEFI should be reported and documented in a line list.</p>
  a2249-4863, 2278-7135